BioCentury
ARTICLE | Clinical News

Arbaclofen placarbil: Phase III started

August 8, 2011 7:00 AM UTC

XenoPort disclosed in its 2Q11 earnings that it began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate twice-daily 15, 30 and 45 mg arbaclofen placarbil for 13 weeks in about 200 p...